Table 3.
Some fish oil composition found in current supplements on the market (data extracted from ref. [71]).
| FAME * | Sample 1 ¶ | Sample 2 ¶ | Sample 3 ¶ | Sample 4 ¶ | Sample 5 ¶ | Sample 6 ¶ |
|---|---|---|---|---|---|---|
| SFA | 21.92 ± 0.05 | 3.66 ± 0.10 | 32.00 ± 0.17 | 23.52 ± 0.14 | 26.28 ± 0.21 | 31.49 ± 0.13 |
| MUFA | 19.49 ± 0.20 | 17.27 ± 0.23 | 52.60 ± 0.14 | 16.34 ± 0.06 | 1.03 ± 0.04 | 26.18 ± 0.03 |
| PUFA | 55.89 ± 0.25 | 77.72 ± 0.23 | 11.51 ± 0.22 | 57.61 ± 0.05 | 59.53 ± 0.19 | 41.22 ± 0.11 |
| PUFA ω-6 | 4.58 ± 0.20 | 5.93 ± 0.16 | 2.12 ± 0.05 | 4.15 ± 0.09 | 12.39 ± 0.14 | 3.29 ± 0.10 |
| PUFA ω-3 | 52.01 ± 0.31 | 72.48 ± 0.51 | 9.38 ± 0.18 | 54.01 ± 0.06 | 59.06 ± 0.18 | 37.93 ± 0.15 |
| total TFA | 2.00 ± 0.07 | 0.66 ± 0.04 | 3.89 ± 0.10 | 1.98 ± 0.15 | 1.25 ± 0.02 | 1.12 ± 0.13 |
| TFA ω-3 | 1.40 ± 0.10 | 0.27 ±0.01 | 2.43 ± 0.09 | 1.30 ± 0.14 | 1.13 ± 0.03 | 0.27 ± 0.08 |
* Fatty acid methyl ester (FAME) contents (% rel.); ¶ Samples are the interior of capsules from different supplements (1–6) marketed in Spain and Italy. Analyses of the same capsule content performed in triplicates (n = 3); TFA ω-3 correspond to mono-trans isomers.